This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Black, M. T.
Right arrow Articles by Miossec, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Black, M. T.
Right arrow Articles by Miossec, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3339-3349, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00496-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases {triangledown}

Michael T. Black,* Thérèse Stachyra,{dagger} Denis Platel,{dagger} Anne-Marie Girard, Monique Claudon, Jean-Michel Bruneau, and Christine Miossec

Novexel S.A., Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France

Received 16 April 2008/ Returned for modification 21 June 2008/ Accepted 2 July 2008

NXL101 is one of a new class of quinoline antibacterial DNA gyrase and topoisomerase IV inhibitors showing potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains. NXL101 inhibited topoisomerase IV more effectively than gyrase from Escherichia coli, whereas the converse is true of enzymes from Staphylococcus aureus. This apparent target preference is opposite to that which is associated with most fluoroquinolone antibiotics. In vitro isolation of S. aureus mutants resistant to NXL101 followed by cloning and sequencing of the genes encoding gyrase and topoisomerase IV led to the identification of several different point mutations within, or close to, the quinolone resistance-determining region (QRDR) of GyrA. However, the mutations were not those that are most frequently associated with decreased sensitivity to quinolones. A fluoroquinolone-resistant mutant variant of gyrase generated in vitro was highly resistant to inhibition by the fluoroquinolones ciprofloxacin and moxifloxacin but remained fully susceptible to inhibition by NXL101. Two mutant gyrases constructed in vitro, with mutations in gyrA engineered according to those most frequently found in S. aureus strains resistant to NXL101, were insensitive to inhibition by NXL101 and had a diminished sensitivity to ciprofloxacin and moxifloxacin. Certain combinations of mutations giving rise to NXL101 resistance and those giving rise to fluoroquinolone resistance may be mutually exclusive.

* Corresponding author. Mailing address: Novexel S.A., Parc Biocitech, 102 Avenue Gaston Roussel, 93230 Romainville, France. Phone: 33 1 5714 0731. Fax: 33 1 4846 3926. E-mail: Mick.Black{at}Novexel.com

{triangledown} Published ahead of print on 14 July 2008.

{dagger} T.S. and D.P. contributed equally to this work.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3339-3349, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00496-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»